TW202334168A - 大環化合物及其作為激酶抑制劑之用途 - Google Patents

大環化合物及其作為激酶抑制劑之用途 Download PDF

Info

Publication number
TW202334168A
TW202334168A TW112100378A TW112100378A TW202334168A TW 202334168 A TW202334168 A TW 202334168A TW 112100378 A TW112100378 A TW 112100378A TW 112100378 A TW112100378 A TW 112100378A TW 202334168 A TW202334168 A TW 202334168A
Authority
TW
Taiwan
Prior art keywords
alkyl
pharmaceutically acceptable
compound
acceptable salt
group
Prior art date
Application number
TW112100378A
Other languages
English (en)
Chinese (zh)
Inventor
景榮 崔
元金 芮
伊凡 W 羅傑斯
大勇 翟
Original Assignee
美商榮山醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商榮山醫藥股份有限公司 filed Critical 美商榮山醫藥股份有限公司
Publication of TW202334168A publication Critical patent/TW202334168A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW112100378A 2022-01-05 2023-01-05 大環化合物及其作為激酶抑制劑之用途 TW202334168A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263296705P 2022-01-05 2022-01-05
US63/296,705 2022-01-05
US202263435654P 2022-12-28 2022-12-28
US63/435,654 2022-12-28

Publications (1)

Publication Number Publication Date
TW202334168A true TW202334168A (zh) 2023-09-01

Family

ID=87074235

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112100378A TW202334168A (zh) 2022-01-05 2023-01-05 大環化合物及其作為激酶抑制劑之用途

Country Status (10)

Country Link
US (1) US20250074920A1 (https=)
EP (1) EP4460498A4 (https=)
JP (1) JP2025503592A (https=)
KR (1) KR20240131416A (https=)
AU (1) AU2023204770A1 (https=)
CA (1) CA3246487A1 (https=)
IL (1) IL314070A (https=)
MX (1) MX2024008413A (https=)
TW (1) TW202334168A (https=)
WO (1) WO2023133375A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024266587A1 (en) * 2023-05-02 2025-09-11 Blossomhill Therapeutics, Inc. Egfr inhibitors for treating disease
WO2025212729A1 (en) * 2024-04-03 2025-10-09 Blossomhill Therapeutics, Inc. Macrocyclic compounds and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03376B (me) * 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
US20160031888A1 (en) * 2013-03-13 2016-02-04 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
ES2933350T3 (es) * 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
TWI707852B (zh) * 2015-09-02 2020-10-21 美商林伯士拉克許米公司 Tyk2 抑制劑及其用途
EP4178958A4 (en) * 2020-07-10 2024-12-11 Blossomhill Therapeutics, Inc. MACROCYCLES AND THEIR USE

Also Published As

Publication number Publication date
CA3246487A1 (en) 2023-07-13
MX2024008413A (es) 2024-09-17
US20250074920A1 (en) 2025-03-06
EP4460498A1 (en) 2024-11-13
EP4460498A4 (en) 2026-03-25
JP2025503592A (ja) 2025-02-04
AU2023204770A1 (en) 2024-07-18
KR20240131416A (ko) 2024-08-30
WO2023133375A1 (en) 2023-07-13
IL314070A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
JP7644517B2 (ja) Kras突然変異型タンパク質阻害剤
JP2023179539A (ja) タンパク質キナーゼのモジュレータとしてのジアリール大環状化合物
EP2855456B1 (en) Complement pathway modulators and uses thereof
ES2699948T3 (es) Compuestos de heteroarilo sustituido y métodos de uso
WO2021249563A1 (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
KR20230121773A (ko) 거대고리 화합물 및 그의 용도
JP2019534337A (ja) 含窒素複素環化合物、製造方法、中間体、医薬組成物及び応用
WO2018045956A1 (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
CN107735399A (zh) 作为蛋白质激酶的调节剂的手性二芳基大环
TW201313717A (zh) 作為c-Kit激酶抑制劑之化合物及組合物
CN104024254A (zh) 作为c-Kit激酶抑制剂的化合物和组合物
KR20230142745A (ko) Cdk2 억제제 및 그의 사용 방법
TW202334168A (zh) 大環化合物及其作為激酶抑制劑之用途
WO2015058661A1 (zh) Bcr-abl激酶抑制剂及其应用
TW202216730A (zh) 大環化合物及其用途
TW202413377A (zh) 吲唑巨環化合物及其用途
TW202321239A (zh) 作為hpk1抑制劑用於治療癌症之經取代的吡𠯤—2—甲醯胺
WO2016023401A1 (zh) 一种含磷吡啶并嘧啶酮类化合物或其药学上可接受的盐、药物组合物及其应用
WO2023165570A1 (zh) 环烷基或杂环基取代的杂芳基化合物及其组合物及用途
CN111518082B (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
EP4429770A1 (en) Btk inhibitors
TW202132313A (zh) 咪唑烷酮類化合物、包含其的醫藥組合物及其應用
TW202448452A (zh) 用於治療疾病之egfr抑制劑
KR20170095243A (ko) Pi3kbeta 저해제로서의 헤테로사이클릴 연결된 이미다조피리다진 유도체
TWI652265B (zh) 氮雜吲哚衍生物